Literature DB >> 21206545

Ramelteon prior to a short evening nap impairs neurobehavioral performance for up to 12 hours after awakening.

Daniel A Cohen1, Wei Wang, Elizabeth B Klerman, Shantha M W Rajaratnam.   

Abstract

STUDY
OBJECTIVES: Planned naps can improve performance when the habitual or nocturnal sleep schedule is disrupted. It may be difficult, however, to achieve sleep during a nap, particularly during the circadian peak in alertness in the early evening. Prior studies with the melatonin agonist, ramelteon, reported that this hypnotic does not impair neurobehavioral performance. We tested whether ramelteon could improve nap efficiency in the early evening and subsequent performance during a simulated 8-h night shift.
METHODS: 10 healthy volunteers aged 19-31 years participated in an inpatient randomized, double-blind, placebo-controlled crossover study. Ramelteon 8 mg or placebo was administered 30 min prior to a 2-h nap opportunity commencing 13 h after each individual's habitual morning wake time.
RESULTS: Ramelteon did not significantly affect sleep efficiency during the nap prior to the night shift. Following the nap, ramelteon was associated with significantly worse neurobehavioral performance on assessments immediately following the nap and during the simulated night shift.
CONCLUSIONS: Although ramelteon did not significantly affect sleep during the nap, it was associated with significant impairments in neurobehavioral performance for up to 12 h after administration. High homeostatic sleep pressure combined with the circadian performance nadir may increase the vulnerability to hypnotic-induced neurobehavioral impairments. The findings do not support the use of ramelteon prior to an evening prophylactic nap, as there may be residual effects that last for several hours. Furthermore, this study highlights the pitfalls of applying side-effect profiles obtained in one context to another.

Entities:  

Keywords:  Ramelteon; circadian; shift work; sleep deprivation

Mesh:

Substances:

Year:  2010        PMID: 21206545      PMCID: PMC3014243     

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  25 in total

1.  Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.

Authors:  Aziz Karim; Dwain Tolbert; Charlie Cao
Journal:  J Clin Pharmacol       Date:  2006-02       Impact factor: 3.126

2.  The effects of ramelteon in a first-night model of transient insomnia.

Authors:  Gary Zammit; Howard Schwartz; Thomas Roth; Sherry Wang-Weigand; Steve Sainati; Jeff Zhang
Journal:  Sleep Med       Date:  2008-08-08       Impact factor: 3.492

3.  An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.

Authors:  Milton Erman; David Seiden; Gary Zammit; Stephen Sainati; Jeffrey Zhang
Journal:  Sleep Med       Date:  2005-11-23       Impact factor: 3.492

4.  Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.

Authors:  Matthew W Johnson; Patricia E Suess; Roland R Griffiths
Journal:  Arch Gen Psychiatry       Date:  2006-10

5.  Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats.

Authors:  Keisuke Hirai; Muneto Kita; Hiroyuki Ohta; Hisao Nishikawa; Yuu Fujiwara; Shigenori Ohkawa; Masaomi Miyamoto
Journal:  J Biol Rhythms       Date:  2005-02       Impact factor: 3.182

6.  The sleep-promoting action of ramelteon (TAK-375) in freely moving cats.

Authors:  Masaomi Miyamoto; Hisao Nishikawa; Yayoi Doken; Keisuke Hirai; Osamu Uchikawa; Shigenori Ohkawa
Journal:  Sleep       Date:  2004-11-01       Impact factor: 5.849

7.  Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.

Authors:  Gary Zammit; Milton Erman; Sherry Wang-Weigand; Stephen Sainati; Jeffrey Zhang; Thomas Roth
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

8.  A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia.

Authors:  Thomas Roth; David Seiden; Sherry Wang-Weigand; Jeffrey Zhang
Journal:  Curr Med Res Opin       Date:  2007-05       Impact factor: 2.580

9.  Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice.

Authors:  Masaomi Miyamoto
Journal:  Neurosci Lett       Date:  2006-05-24       Impact factor: 3.197

10.  Acute sleep deprivation and circadian misalignment associated with transition onto the first night of work impairs visual selective attention.

Authors:  Nayantara Santhi; Todd S Horowitz; Jeanne F Duffy; Charles A Czeisler
Journal:  PLoS One       Date:  2007-11-28       Impact factor: 3.240

View more
  4 in total

1.  Ramelteon for Insomnia Related to Attention-Deficit/Hyperactivity Disorder (ADHD).

Authors:  Rachel E Fargason; Karen Gamble; Kristin T Avis; Rachel C Besing; Cherry W Jackson; Marshall E Cates; Roberta May
Journal:  Psychopharmacol Bull       Date:  2011-05-15

2.  Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects.

Authors:  Monique A J Mets; Juna M de Vries; Lieke M de Senerpont Domis; Edmund R Volkerts; Berend Olivier; Joris C Verster
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

3.  The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers.

Authors:  Akemi Miyata; Kunihiro Iwamoto; Naoko Kawano; Kunihiro Kohmura; Maeri Yamamoto; Branko Aleksic; Kazutoshi Ebe; Akiko Noda; Yukihiro Noda; Shuji Iritani; Norio Ozaki
Journal:  Psychopharmacology (Berl)       Date:  2014-12-24       Impact factor: 4.530

Review 4.  Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders.

Authors:  Wilbur P Trey Williams; Dewey E McLin; Marlene A Dressman; David N Neubauer
Journal:  Pharmacotherapy       Date:  2016-09-01       Impact factor: 4.705

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.